Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K6XI
|
|||
| Drug Name |
Griffithsin
|
|||
| Synonyms |
GRFT
Click to Show/Hide
|
|||
| Drug Type |
Protein/peptide drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-10: B17.1, B18.2] | Phase 1 | [1] | |
| Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] | Preclinical | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | SARS-CoV spike glycoprotein (S) | Target Info | Blocker | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02875119) Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women | |||
| REF 2 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.